NCT07654972PHASE1RecruitingAccepts Healthy Volunteers
A Study of LY4174794 in Participants With Obesity or Overweight Who Are Otherwise Healthy
Eli Lilly and Company
Start Date
6/24/2026
Completion Date
4/1/2029
Summary
The main purpose of this study is to understand how safe and well-tolerated LY4174794 is in participants with obesity or overweight who are otherwise healthy. Blood tests will be performed to check how much LY4174794 gets into the bloodstream and how long it takes the body to eliminate it. Participation in this study will last about 35 to 45 weeks (7 to 11 months).
Eligibility Criteria
Age Range: 18 years to 65 years
Inclusion Criteria:
* Are overtly healthy with no comorbidities related to body mass index (BMI), such as type 2 diabetes mellitus or unstable cardiovascular disease
* Are overweight with a BMI of ≥27 kilogram per meter square (kg/m²), or have obesity with a BMI of ≥30 kg/ m²
* Have had a self-reported stable weight for 3 months prior to screening
Exclusion Criteria:
* Have a history or presence of cardiovascular, respiratory, hepatic, renal, GI, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs, or of constituting a risk when taking the study intervention, or of interfering with the interpretation of data
* Is an individual of childbearing potential (IOCBP)
Interventions
DRUG
LY4174794
DRUG
LY4174794
DRUG
Placebo
Conditions
ObesityOverweight
Locations
ICON Early Phase Services, LLC
San Antonio, Texas 78232
United States
ICON Early Phase Services, LLC
Salt Lake City, Utah 84124
United States
Lilly Centre for Clinical Pharmacology
Singapore, 138623
Singapore